Effect of whole-body hyperthermia on the pharmacokinetics and toxicity of lonidamine in dogs.
The pharmacokinetics and toxicity of intravenous lonidamine were investigated in dogs receiving four cycles of lonidamine (400 or 800 mg/m2) +/- whole-body hyperthermia (WBH). Clearance and volume of distribution in dogs receiving lonidamine during WBH increased 1.6-2.3 and 1.9-3.5-fold respectively, relative to dogs receiving lonidamine under euthermic conditions (p < 0.02). In dogs receiving lonidamine under euthermic conditions or 400 mg/m2 + WBH, the area under the lonidamine concentration versus time curve (AUC) measured during the fourth treatment was 21-58% lower than the first treatment AUC. However, in dogs receiving 800 mg/m2 + WBH, the fourth treatment AUC was four-fold higher than the first treatment AUC (p < 0.02). This suggests repeated exposure to 800 mg/m2 lonidamine and WBH impairs lonidamine metabolism. Weakness, hypoglycaemia, and elevations in amylase, alanine aminotransferase, alkaline phosphatase and bilirubin were more severe or occurred exclusively in dogs receiving 800 mg/m2 + WBH. Since these changes were attributable to marked AUC increases, which occurred secondary to repeated exposure to 800 mg/m2 lonidamine during WBH, 400 mg/m2 was identified as the maximum tolerable dose to be administered intravenously to dogs during WBH.
Price
G S
GS
Department of Companion Animal and Special Services Medicine, College of Veterinary Medicine, North Carolina State University, Raleigh 27606, USA.
Page
R L
RL
Riviere
J E
JE
Cline
J M
JM
Thrall
D E
DE
D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D000681:Amylases / Q000097:blood; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000633:toxicity*; D001663:Bilirubin / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D002245:Carbon Dioxide / Q000097:blood; D003402:Creatine Kinase / Q000097:blood; D004285:Dogs; D006979:Hyperthermia, Induced; D007008:Hypokalemia / Q000209:etiology; D007191:Indazoles / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000633:toxicity*; D008099:Liver / Q000187:drug effects / Q000473:pathology; D012798:Sialorrhea / Q000209:etiology; D014508:Urea / Q000097:blood
D000970:Antineoplastic Agents; D001786:Blood Glucose; D007191:Indazoles; D002245:Carbon Dioxide; D014508:Urea; D000410:Alanine Transaminase; D003402:Creatine Kinase; D000469:Alkaline Phosphatase; D000681:Amylases; D001663:Bilirubin; C016371:lonidamine